Genprex (GNPX) Return on Capital Employed (2017 - 2025)
Genprex (GNPX) posted quarterly Return on Capital Employed of 541.69% for Q1 2025, down 18586.0% year-over-year from N/an in Q1 2024, and up 61.33% quarter-over-quarter from 1400.76% in Q4 2024.
Genprex (GNPX) Return on Capital Employed (2017 - 2025) Analysis & Trends
Genprex's Return on Capital Employed history runs 9 years deep, the most recent figure standing at 541.69% for Q1 2025.
- In Q1 2025, Return on Capital Employed fell 18586.0% year-over-year to 541.69%; the TTM figure through Mar 2025 stood at 541.69% (down 18586.0% YoY), while the FY2025 annual figure was 312.37%, up 12035.0% from the prior year.
- Return on Capital Employed for Q1 2025 stood at 541.69%, up from 1400.76% in the prior quarter.
- The five-year high for Return on Capital Employed was 35.43% in Q2 2021, with the low at 1400.76% in Q4 2024.
- The 5-year median for Return on Capital Employed is 143.46% (2023), against an average of 280.18%.
- The sharpest annual moves came in 2021 and 2024: Return on Capital Employed surged 6161 bps in 2021, then sank 110221 bps in 2024.
- Genprex's Return on Capital Employed stood at 45.31% in 2021, then tumbled by 113 bps to 96.46% in 2022, then sank by 209 bps to 298.54% in 2023, then tumbled by 369 bps to 1400.76% in 2024, then jumped by 61 bps to 541.69% in 2025.
- Business Quant data shows GNPX's Return on Capital Employed at 541.69% in Q1 2025, 1400.76% in Q4 2024, and 756.75% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 26.09% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -50.93% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 7.88% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -6.85% |
| 10 | Genprex | 1.89 Mn | -13.27 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | -541.69% |
| Dec 31, 2024 | -1,400.76% |
| Sep 30, 2024 | -756.75% |
| Jun 30, 2024 | -358.60% |
| Mar 31, 2024 | -355.83% |
| Dec 31, 2023 | -298.54% |
| Sep 30, 2023 | -265.24% |
| Jun 30, 2023 | -190.74% |
| Mar 31, 2023 | -143.46% |
| Dec 31, 2022 | -96.46% |
| Sep 30, 2022 | -80.55% |
| Jun 30, 2022 | -61.07% |
| Mar 31, 2022 | -50.29% |
| Dec 31, 2021 | -45.31% |
| Sep 30, 2021 | -38.75% |
| Jun 30, 2021 | -35.43% |
| Mar 31, 2021 | -43.60% |
| Dec 31, 2020 | -66.75% |
| Sep 30, 2020 | -64.03% |
| Jun 30, 2020 | -60.37% |